Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

(2021) Luis Paz-Ares et al.   LANCET ONCOLOGY

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients

(2021) Kangning Peng et al.   ANNALS OF PHARMACOTHERAPY

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

(2021) Sebastiano Buti et al.   EUROPEAN JOURNAL OF CANCER

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

(2021) Konstantinos Rounis et al.   PLoS One

Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150

(2021) Ashley M. Hopkins et al.   BRITISH JOURNAL OF CANCER

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations

(2021) Ichidai Tanaka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors

(2021) Quentin Giordan et al.   Frontiers in Immunology

A role for club cells in smoking-associated lung adenocarcinoma

(2021) Sabine J. Behrend et al.   European Respiratory Review

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

(2020) M. Chalabi et al.   ANNALS OF ONCOLOGY

Interaction between drugs and the gut microbiome

(2020) Rinse K Weersma et al.   GUT

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non‐small cell lung cancer

(2020) Xiayao Diao   Thoracic Cancer

Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer

(2020) Stephen R. Broderick   Thoracic Surgery Clinics

Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

(2020) Fausto Petrelli et al.   Journal of Clinical Medicine

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

(2020) Dipesh Uprety et al.   Journal of Thoracic Oncology

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

(2020) Bingxi He et al.   Journal for ImmunoTherapy of Cancer

Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

(2020) Ashley M. Hopkins et al.   CLINICAL CANCER RESEARCH

Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications

(2020) Karla A. Lee et al.   EUROPEAN JOURNAL OF CANCER

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma

(2020) Giuseppe Lamberti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research

(2020) Kamila Wojas-Krawczyk et al.   Frontiers in Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer

(2019) Taiki Hakozaki et al.   Oncology Letters

Gut microbiome and cancer immunotherapy

(2019) Weina Li et al.   CANCER LETTERS

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer

(2019) Sha Zhao et al.   LUNG CANCER

Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified

(2019) Giovanni Bruno et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer

(2018) Martin Reck   Immunotherapy

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extensive impact of non-antibiotic drugs on human gut bacteria

(2018) Lisa Maier et al.   NATURE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Immunotherapy for lung cancer

(2016) Antonius Steven et al.   RESPIROLOGY

Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments

(2014) Carson Ka-Lok Lo et al.   BMC Medical Research Methodology